Wang Haiyue, Zhu Yanli, Sun Wei, Yang Xin, Liu Xinying, Chi Kaiwen, Huang Xiaozheng, Zhou Lixin, Cai Weijing, Lin Dongmei
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Shanghai Tongshu Biotechnology Co., Ltd., Shanghai 200120, China.
Cancers (Basel). 2023 Nov 29;15(23):5649. doi: 10.3390/cancers15235649.
Histologic transformation (HT) is common following targeted therapy in adenocarcinoma. However, whether the transformed tumor is a new component or a combined neuroendocrine carcinoma (C-NEC) remains controversial. We aimed to explore the relationship between pulmonary C-NEC and HT. Macro-dissection was performed on different components of surgically resected C-NEC samples. Molecular alterations and clonal evolution were analyzed using whole exome sequencing (WES). The gene statuses for and were determined using immunohistochemistry (IHC) and WES to analyze the relationship between C-NEC and reported HT. Sixteen combined small-cell lung cancer patients and five combined large-cell neuroendocrine carcinoma patients were enrolled. The frequency of p53 and Rb inactivation, assessed using IHC in NEC and non-NEC components, was 76.2/76.2% and 66.7/61.9%, respectively. The expression consistency between the components was 81.0 and 85.7% for p53 and Rb, respectively. The frequencies of , , and mutations, assessed using WES in NEC and non-NEC components, were 81.0/81.0%, 28.6/28.6%, and 42.9/42.9%, respectively. The concordance rates for , , and were 90.5, 71.4, and 90.5%, respectively. The consistency rate between IHC and WES was 81.0 and 61.9% for and , respectively. The different components had a common clonal origin for the 21 C-NECs in the clonal analysis, consistent with previous studies on HT. Our study shows that IHC is more sensitive for Rb detection and C-NEC, and the reported HT may be due to differences in evaluations between pathologist and clinicians. Assessing the p53/Rb and status for such cases would help in recognizing potential transformation cases or uncovering potential combined components.
组织学转化(HT)在腺癌靶向治疗后很常见。然而,转化后的肿瘤是新成分还是合并性神经内分泌癌(C-NEC)仍存在争议。我们旨在探讨肺C-NEC与HT之间的关系。对手术切除的C-NEC样本的不同成分进行大体解剖。使用全外显子组测序(WES)分析分子改变和克隆进化。使用免疫组织化学(IHC)和WES确定 和 的基因状态,以分析C-NEC与报道的HT之间的关系。纳入了16例合并小细胞肺癌患者和5例合并大细胞神经内分泌癌患者。在NEC和非NEC成分中使用IHC评估的p53和Rb失活频率分别为76.2/76.2%和66.7/61.9%。p53和Rb在各成分之间的表达一致性分别为81.0%和85.7%。在NEC和非NEC成分中使用WES评估的 、 和 突变频率分别为81.0/81.0%、28.6/28.6%和42.9/42.9%。 、 和 的一致率分别为90.5%、71.4%和90.5%。IHC和WES之间对于 和 的一致率分别为81.0%和61.9%。在克隆分析中,21例C-NEC的不同成分具有共同的克隆起源,这与先前关于HT的研究一致。我们的研究表明,IHC对Rb检测和C-NEC更敏感,报道的HT可能是由于病理学家和临床医生之间评估的差异。评估此类病例的p53/Rb和 状态将有助于识别潜在的转化病例或发现潜在的合并成分。